What is HC Wainwright's Estimate for COLL Q1 Earnings?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Investment analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a research note issued on Monday, March 24th. HC Wainwright analyst O. Livnat now anticipates that the specialty pharmaceutical company will post earnings of $1.20 per share for the quarter, down from their previous estimate of $1.29. HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical's current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical's Q2 2025 earnings at $1.48 EPS.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million.

A number of other equities research analysts have also commented on the stock. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. Piper Sandler decreased their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.60.

Remove Ads

Collegium Pharmaceutical Stock Up 0.5 %

NASDAQ COLL traded up $0.15 during trading hours on Wednesday, reaching $29.71. 249,570 shares of the company's stock were exchanged, compared to its average volume of 438,298. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical has a one year low of $27.28 and a one year high of $42.29. The company's 50-day moving average is $30.36 and its two-hundred day moving average is $32.42. The company has a market capitalization of $935.45 million, a price-to-earnings ratio of 12.81 and a beta of 0.99.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors have recently bought and sold shares of the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Collegium Pharmaceutical by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company's stock valued at $1,902,000 after acquiring an additional 7,063 shares during the period. Velan Capital Investment Management LP acquired a new stake in Collegium Pharmaceutical during the 4th quarter valued at $822,000. Vident Advisory LLC boosted its position in Collegium Pharmaceutical by 27.8% during the fourth quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company's stock worth $484,000 after purchasing an additional 3,672 shares during the period. Finally, Virtus Fund Advisers LLC increased its holdings in shares of Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after purchasing an additional 565 shares during the last quarter.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares of the company's stock, valued at approximately $3,732,630. This trade represents a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.